Company news

Arcus Biosciences, Inc. news in 2025

Arcus Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

December 12, 2025

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

November 18, 2025

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

October 30, 2025

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

October 30, 2025

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

October 28, 2025

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

October 19, 2025

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

October 12, 2025

Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event

October 6, 2025

Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

September 2, 2025

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

August 20, 2025

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

August 6, 2025

Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

July 10, 2025

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

June 1, 2025

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

May 6, 2025

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

April 23, 2025

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

April 22, 2025

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

February 25, 2025

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

February 18, 2025

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

February 18, 2025

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

February 15, 2025

Calls in 2025

Decks in 2025